Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b

NCT04396340 is registered in ClinicalTrials.gov with Mersana Therapeutics as lead sponsor.

NCT NCT04396340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04396340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b
Lead sponsor
Mersana Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
May 11, 2020
Completion date
September 30, 2022
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonsmall cell lung cancer, ovarian cancer